This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by Medical University of Vienna.
Recruitment status was:  Recruiting
Information provided by:
Medical University of Vienna Identifier:
First received: October 16, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.

Condition Intervention Phase
Uterine Cervical Neoplasms Drug: 18F Fluoroazomycin Arabinoside (FAZA) Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 25
Study Start Date: July 2006
Estimated Study Completion Date: July 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
  • Treatment intention for the purpose of achieving cure
  • Age < 80 years
  • No previous standard or radical hysterectomy

Exclusion Criteria:

  • Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00388687

Contact: Matthias Schuetz, M.D. 00431404005550
Contact: Barbara Bachtiary, Prof. M.D 00431404007676

Medical Universitiy of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676   
Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676   
Principal Investigator: Georgios Karanikas, Prof. M.D.         
Sponsors and Collaborators
Medical University of Vienna
Study Director: Georgios Karanikas, Prof. M.D. Medical Universitiy of Vienna
  More Information Identifier: NCT00388687     History of Changes
Other Study ID Numbers: EK Nr: 241/2006
Study First Received: October 16, 2006
Last Updated: October 16, 2006

Keywords provided by Medical University of Vienna:

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Signs and Symptoms, Respiratory
Signs and Symptoms processed this record on September 21, 2017